Valuation: U.S. Stem Cell, Inc.

Market Cap 661 580.56 539.9 495.43 930.88 63.66K 945.23 6.41K 2.5K 31.29K 2.48K 2.43K 108K P/E 2021
-0.84x
P/E 2022 -0.99x
Enterprise Value 10.08M 8.85M 8.23M 7.56M 14.2M 971M 14.41M 97.77M 38.2M 477M 37.84M 37.02M 1.65B EV / Sales 2021
59.5x
EV / Sales 2022 160x
Free-Float
89.05%
Yield 2021 *
-
Yield 2022 -
1 week 0
Extreme 0
0
1 month 0
Extreme 0
0
Current year 0
Extreme 0
0
1 year 0
Extreme 0
0
3 years 0
Extreme 0
0
5 years 0
Extreme 0
0.01
10 years 0
Extreme 0
0.18
Manager TitleAgeSince
Chief Executive Officer 60 2010-06-23
Director TitleAgeSince
Director/Board Member 74 2017-03-04
Chairman - 2010-11-01
Director/Board Member 60 2011-08-16
Date Insider Type Main position Quantity % Market Cap.
4/25/22 Free

Director

2,500,000 0.5198%
4/25/22
Northstar Biotech Group LLC
OtherCompany 0 0%
3/18/22
Northstar Biotech Group LLC
OtherCompany 0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - -50.00% 661
+0.93%+6.97%+59.60%+68.35% 57.28B
-1.92%+6.03%+40.64%+83.42% 54.99B
-0.46%-1.29%+2.86%+428.78% 23.18B
-2.97%-2.35%-22.53%-16.40% 22.59B
-0.36%+5.73%+24.13%-6.24% 20.46B
-1.34%+0.51%+26.03%-29.41% 17.56B
-1.44%+5.67%+38.77%+504.71% 15.67B
-1.30%-5.02%+170.77%+291.37% 14.46B
-0.50%-0.98%+21.43%+180.07% 13.92B
Average -0.94%+1.15%+40.19%+145.47% 24.01B
Weighted average by Cap. -0.87%+2.10%+39.70%+133.49%

Financials

2021 2022
Net sales 201K 176K 164K 150K 283K 19.33M 287K 1.95M 761K 9.5M 754K 737K 32.86M 82.05K 72.06K 67.02K 61.5K 116K 7.9M 117K 796K 311K 3.88M 308K 301K 13.43M
Net income -3.29M -2.89M -2.69M -2.46M -4.63M -317M -4.7M -31.89M -12.46M -156M -12.34M -12.08M -538M -2.86M -2.51M -2.33M -2.14M -4.02M -275M -4.09M -27.72M -10.83M -135M -10.73M -10.5M -468M
Net Debt 8.93M 7.84M 7.29M 6.69M 12.57M 860M 12.77M 86.6M 33.83M 423M 33.52M 32.79M 1.46B 10.08M 8.85M 8.23M 7.55M 14.19M 971M 14.41M 97.76M 38.19M 477M 37.84M 37.02M 1.65B
Logo U.S. Stem Cell, Inc.
U.S. Stem Cell, Inc. is a biotechnology company. The Company is focused on the discovery, development and subject to regulatory approval and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its product candidates are MyoCell, MyoCell SDF-1 and Adipocell. MyoCell and MyoCell SDF-1 product candidates are clinical therapies designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The myoblast cells to be injected are gene-modified prior to injection by an adenovirus vector so that they will release extra quantities of stromal derived factor - 1 or SDF-1 protein. The Adipocell product candidate is a cell therapy kit with multiple possible treatment applications using autologous adipose cells. It is also investigating the use of adipose cells in a variety of clinical applications.
Employees
11
Date Price Change Volume
26-07-24 US$0.000001 -99.00% 54,804
  1. Stock Market
  2. Stocks
  3. USRM Stock